Cocrystal Pharma (COCP) grants 24,615 stock options to director Frost

Rhea-AI Filing Summary

Cocrystal Pharma, Inc. reported that director and 10% owner Phillip Frost received a grant of stock options. On January 9, 2026, he was awarded 24,615 non-qualified stock options to buy Cocrystal common stock at an exercise price of $1.10 per share, for no upfront cost. These options were approved by the company’s Compensation Committee under the 2025 Equity Incentive Plan.

Half of the options vest and become exercisable on January 9, 2027, with the remaining half vesting in eight equal quarterly installments starting March 31, 2027, as long as Frost continues to serve as a director on each vesting date. The filing notes that this report does not include securities owned directly by OPKO Health, Inc., for which Frost disclaims beneficial ownership except for any pecuniary interest.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FROST PHILLIP MD ET AL

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	24,615	$0.00	--

Holdings After Transaction: Stock Options (Right to Buy) — 24,615 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FROST PHILLIP MD ET AL

(Last) (First) (Middle)

4400 BISCAYNE BLVD

(Street)

MIAMI FL 33137-3227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cocrystal Pharma, Inc. [ COCP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)(1)	$1.1	01/09/2026		A		24,615		(1)	01/09/2036	Common Stock	24,615	$0	24,615	D

Explanation of Responses:

1. The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

Remarks:

This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

	/s/ Phillip Frost, MD ET AL	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cocrystal Pharma (COCP) report for Phillip Frost?

Cocrystal Pharma reported that director and 10% owner Phillip Frost received a grant of 24,615 non-qualified stock options on January 9, 2026.

What are the key terms of Phillip Frosts stock options from Cocrystal Pharma?

The options are Stock Options (Right to Buy) Cocrystal common stock at an exercise price of $1.10 per share, granted for a price of $0 for the derivative itself, and they expire on January 9, 2036.

How and when do Phillip Frosts Cocrystal Pharma options vest?

According to the filing, one-half of the non-qualified stock options vest and become exercisable on January 9, 2027. The remaining half vest in eight equal quarterly installments starting on March 31, 2027, provided Frost continues serving as a director on each vesting date.

Under which plan were the Cocrystal Pharma options to Phillip Frost granted?

The non-qualified stock options were granted under Cocrystal Pharmas 2025 Equity Incentive Plan, and their exercisability is subject to execution of the companys form of Non-Qualified Stock Option Agreement.

How many Cocrystal Pharma derivative securities does Phillip Frost hold after this transaction?

After the reported grant, Frost beneficially owns 24,615 derivative securities (stock options) directly, as shown in the derivative securities table.

Does this Form 4 include Cocrystal Pharma securities held by OPKO Health, Inc.?

No. The remarks state that this report does not include any securities owned directly by OPKO Health, Inc., where Frost is Chairman and CEO. He disclaims beneficial ownership of those securities except to the extent of any pecuniary interest.

Was Phillip Frosts Cocrystal Pharma option grant exempt from Section 16(b)?

Yes. The explanation notes that the grant of non-qualified stock options was exempt from Section 16(b) under Rule 16b-3, as it was approved by Cocrystals Compensation Committee of the Board of Directors.